Related by context. All words. (Click for frequent words.) 70 metabolic parameters 68 lipid profiles 68 lipid parameters 67 atherogenic dyslipidemia 66 metabolic syndrome MetS 66 elevated triglycerides 65 modifiable lifestyle 64 lipid abnormalities 64 cardio metabolic 64 carotid IMT 64 hyperglycaemia 64 plasma lipids 64 lipid levels 64 glycemia 64 metabolic abnormalities 64 cardiovascular morbidity 64 metabolic dysfunction 64 serum lipids 63 abdominal adiposity 63 central adiposity 63 dyslipidaemia 63 adiposity 63 obesity insulin resistance 63 arterial stiffness 63 blood lipids 63 body fatness 63 plasma triglycerides 62 glucose homeostasis 62 abdominal obesity 62 impaired glucose metabolism 62 antioxidant supplementation 62 extrapyramidal symptoms 62 gallstone disease 62 metabolic disturbances 62 metabolic syndrome 62 serum lipid levels 62 glycosylated hemoglobin HbA1c 62 postoperative AF 62 serum lipid 62 MetS 62 dietary patterns 62 fasting glucose levels 62 HbA1c levels 61 fasting insulin 61 fasting plasma glucose 61 insulin resistance syndrome 61 cardiometabolic 61 potentially modifiable 61 HDL cholesterol triglycerides 61 colorectal adenoma 61 diabetic microvascular complications 61 glycated hemoglobin levels 61 autonomic dysfunction 61 insulin resistance 61 antihypertensive therapy 61 modifiable risk 61 plasma lipid 61 NAFLD 61 hyperhomocysteinemia 61 nonfasting triglyceride levels 61 elevated triglyceride levels 61 macrovascular 61 serum triglycerides 61 abnormal lipid 61 macrovascular events 61 dyslipidemias 61 cardiorespiratory fitness 61 serum cholesterol 61 liver histology 60 T2D 60 growth hormone secretion 60 inflammatory biomarkers 60 endothelial function 60 left ventricular diastolic 60 diabetes hyperlipidemia 60 subclinical atherosclerosis 60 Lp PLA 2 60 serum leptin 60 psychosocial functioning 60 exploratory endpoints 60 tHcy 60 co morbidities 60 fasting plasma glucose FPG 60 urinary oxalate 60 inflammatory markers 60 glycosylated hemoglobin levels 60 visceral adiposity 60 microalbuminuria 60 cardioembolic stroke 60 Stop Hypertension diet 60 triacylglycerol concentrations 60 intestinal motility 60 prostate carcinogenesis 60 apolipoprotein B 60 dietary sodium 60 glycaemia 60 HbA 1c 60 neurocognitive functioning 60 microvascular complications 60 dietary glycemic index 59 type2 diabetes 59 T2DM 59 postprandial glucose 59 subclinical hypothyroidism 59 cardiovascular disease hypertension 59 serum vitamin D 59 diabetes mellitus DM 59 HbA1C 59 hemoglobin A1c levels 59 glycemic control 59 serum phosphate 59 lipohypertrophy 59 serum GGT 59 HRQL 59 cardiac autonomic 59 cardio respiratory fitness 59 atherogenic 59 Stop Hypertension DASH diet 59 intima media thickness 59 macrovascular disease 59 fasting hyperglycemia 59 comorbid conditions 59 lipoprotein metabolism 59 dyslipidemia 59 hepatic steatosis 59 serum PTH 59 thickness CIMT 59 disease NAFLD 59 glucose insulin 59 depressive symptomatology 59 HbA 1c levels 59 abnormal glucose tolerance 59 thromboembolic disease 59 lipoprotein levels 59 diabetes dyslipidemia 59 triglyceride concentrations 59 carotid intima media 59 T1DM 59 affective disorders 59 prognostic markers 59 intestinal microflora 59 carotid atherosclerosis 59 carotid plaque 59 serum BDNF 59 nonalcoholic steatohepatitis 59 atherothrombotic 59 atherosclerotic disease 59 hyperglycemia 59 probiotic supplementation 59 carbohydrate metabolism 58 hypercalciuria 58 DASH Dietary Approaches 58 adiponectin levels 58 serum triglyceride levels 58 fasting plasma 58 lipid disorders 58 magnesium intake 58 BMI z 58 dietary DHA 58 carotid plaques 58 atherothrombosis 58 adenoma recurrence 58 overt nephropathy 58 colorectal carcinogenesis 58 impaired cognition 58 alanine aminotransferase ALT 58 dysglycemia 58 bile acid metabolism 58 albuminuria 58 somatic symptoms 58 LDL HDL 58 impaired fasting glucose 58 Fasting glucose 58 nonfasting triglycerides 58 hypertension diabetes mellitus 58 dietary fatty acids 58 LDL cholesterol lowering 58 NNT = 58 recurrent venous thromboembolism 58 hippocampal volume 58 improves glycemic 58 abdominal girth 58 cardiometabolic syndrome 58 bulimia nervosa 58 lipid lowering agents 58 ABCB1 58 atherosclerosis regression 58 blood glucose concentrations 58 neurocognitive function 58 serum uric acid 58 CaPre ™ 58 triacylglycerol 58 abnormal lipids 58 prostate cancer CaP 58 impaired glucose tolerance 58 dietary intakes 58 glycemic variability 58 morphometric vertebral fractures 58 APOE genotype 58 macrovascular complications 58 chronic periodontitis 58 endothelial activation 58 comorbid depression 58 HOMA IR 58 morbidity mortality 58 dietary carbohydrate 58 hyperinsulinemia 58 mechanistic studies 58 folate deficiency 58 cardiovascular mortality 58 serum urate levels 57 A1c levels 57 cross sectionally 57 airway hyperresponsiveness 57 disordered eating behaviors 57 triglyceride levels 57 density lipoprotein cholesterol 57 flow mediated dilation 57 plasma folate 57 serum folate concentrations 57 fasting serum 57 dietary interventions 57 echocardiographic parameters 57 endogenous hormones 57 pharmacological therapies 57 hemoglobin A1c HbA1c 57 dietary intake 57 etiologic 57 neurodevelopmental outcome 57 genetic polymorphisms 57 etiological 57 adrenal function 57 salivary cortisol 57 Cardiorespiratory fitness 57 blood Phe levels 57 STAT4 57 hyperlipidemia 57 impaired endothelial 57 pharmacodynamic parameters 57 primary hyperparathyroidism 57 Nonalcoholic Fatty Liver Disease 57 cardiovascular disease CVD 57 gastric carcinogenesis 57 hypercholesterolemia 57 systolic hypertension 57 antidiabetic medications 57 prognostic indicators 57 microvascular disease 57 daytime alertness 57 serum calcium 57 distal colon cancer 57 β blockers 57 pramlintide 57 HbA 1C 57 Chronic insomnia 57 Hp2 2 57 tissue oxygenation 57 intact parathyroid hormone 57 davalintide 57 pharmacokinetic PK profile 57 hsCRP 57 glycemic load 57 vascular dysfunction 57 genetic loci 57 Trandolapril 57 pulmonary exacerbations 57 platelet reactivity 57 elevated IOP 57 PAOD 57 HbA1C levels 57 intestinal permeability 57 Lp PLA2 57 urinary albumin 57 clinically meaningful reductions 57 nonalcoholic steatohepatitis NASH 57 glycosylated hemoglobin 57 CHD mortality 57 Depressive symptoms 57 vascular inflammation 57 HMG CoA reductase inhibitors 57 thyrotropin 57 adiponectin concentrations 57 polyp recurrence 57 HIV HCV coinfected 57 diabetes mellitus 57 antidiabetic therapy 57 elevated LDL cholesterol 57 DVT PE 57 underlying pathophysiology 57 ventricular remodeling 57 IPAH 57 oxidative stress markers 57 Non Alcoholic Fatty 57 neuropsychiatric symptoms 57 macroalbuminuria 57 psychopathological symptoms 57 serologically active patients 57 pramlintide metreleptin combination 57 artery elasticity 57 dopamine D2 receptors 57 familial clustering 57 HDL2 57 IL6 57 HRQoL 57 antidiabetic medication 57 carotid bruit 57 NPH insulin 57 atypical neuroleptics 57 atherogenesis 57 antiarrhythmic drug 56 telomere lengths 56 elevated homocysteine 56 STEP BD 56 postprandial glycemia 56 clinicopathological 56 Dyslipidemia 56 Stop Hypertension DASH 56 Primary endpoints 56 serum parathyroid hormone 56 LDL cholesterol concentrations 56 serum glucose 56 symptomatic VTE 56 Hypercholesterolemia 56 alcoholic fatty liver 56 insulin sensitivity 56 lipoprotein profiles 56 coronary stenosis 56 Meta analyzes 56 fat oxidation 56 antidiabetic drugs 56 colorectal neoplasia 56 glucose intolerance 56 onset diabetes mellitus 56 cardiovascular disease 56 serum homocysteine 56 thyrotropin levels 56 CLA supplementation 56 euthymic patients 56 plasma adiponectin 56 QTc intervals 56 psychiatric comorbidities 56 peptide YY 56 AGHD 56 hyperphenylalaninemia HPA due 56 serum insulin 56 AST ALT 56 albumin excretion rate 56 tolvaptan 56 homocysteine concentrations 56 Erythropoietic therapies may 56 convergent validity 56 Homocysteine 56 residual confounding 56 endophenotypes 56 alexithymia 56 glomerular filtration 56 transferrin saturation 56 amnestic MCI 56 hepatic glucose production 56 Hypertriglyceridemia 56 biologic pathways 56 nitrotyrosine 56 baseline HbA1c 56 Stop Hypertension 56 dyslipidemia hypertension 56 waist circumference WC 56 NYHA functional class 56 monogenic 56 arterial stiffening 56 periprocedural MI 56 cognitive function 56 anthropometric measures 56 disordered eating patterns 56 atherosclerotic vascular disease 56 ATACAND 56 saturated fat intake 56 atherothrombotic disease 56 Metabolic Syndrome 56 Cystatin C 56 atherogenic lipids 56 biologic plausibility 56 dietary antioxidants 56 hyperoxaluria 56 albumin excretion 56 left ventricular systolic 56 intracranial hemorrhage ICH 56 plasma homocysteine 56 apolipoproteins 56 serum concentrations 56 pharmacodynamic endpoints 56 endothelial dysfunction 56 overactive bladder symptoms 56 mitochondrial toxicity 56 K DOQI 56 Haptoglobin 56 Albuminuria 56 hypercholesterolaemia 56 sociodemographic factors 56 fatal IHD 56 LDL Cholesterol 56 blood glucose levels 56 pharmacological therapy 56 hepatic fibrosis 56 bone metabolism 56 adipocyte 56 fasting blood glucose 56 comorbidities 56 dietary modification 56 maximally tolerated doses 56 Secondary efficacy endpoints 56 Angiotensin converting enzyme 56 Coronary artery calcification 56 STRIDE PD 56 colorectal adenomas 56 hsCRP levels 56 ACC AHA 56 behavioral disinhibition 56 hyperlipidaemia 56 glycemic diet 56 neuropathological 56 metformin sulfonylurea 56 nutrient intake 56 Observational studies 56 psychosocial variables 56 serum phosphate levels 56 lowering blood glucose 56 cortisol secretion 56 sociodemographic characteristics 56 KDOQI 56 antiplatelet agents 56 ADCS CGIC 56 proliferative diabetic retinopathy 56 pharmacological approaches 56 thrombophilia 56 adenotonsillectomy 56 Carbohydrate intake 56 elevated ALT 56 Waist circumference 56 urolithiasis 56 Endothelial function 56 cirrhotic patients 56 aminotransferases 56 antihypertensive medications 56 erection hardness 56 folate intake 56 preserved ejection fraction 56 Genetic predisposition 56 MMSE scores 56 serum IGF 56 plasma renin activity 56 comorbidity 56 neuropsychiatric diseases 56 Cognitive impairment 56 cardiac biomarkers 56 Triglyceride levels 56 HRQOL 56 platelet activation 55 Thiazolidinediones 55 sUA 55 conditional logistic regression 55 Nocturia 55 fructose intake 55 clinically meaningful improvements 55 induce insulin resistance 55 lipid metabolism 55 obstructive coronary artery 55 intracerebral haemorrhage 55 urinary symptoms 55 prespecified secondary 55 secondary hyperparathyroidism 55 nutrient intakes 55 antipsychotic induced 55 MYH9 55 macrophage infiltration 55 dietary fats 55 waist girth 55 heterozygous familial 55 hemoglobin A1C 55 Neuroticism 55 cardiac dysfunction 55 glucose tolerance 55 diabetes mellitus hypertension 55 elevated uric acid 55 hypothalamic pituitary adrenal axis 55 oral antidiabetic medication 55 coronary artery calcification 55 linoleic acid LA 55 macronutrient intake 55 trans palmitoleic acid 55 hypertension hypercholesterolemia 55 IDDM 55 #mg/dL [001] 55 urinary excretion 55 Impaired Glucose Tolerance 55 pressure natriuresis 55 glycated hemoglobin 55 diabetic dyslipidemia 55 Reynolds Risk Score 55 serum retinol 55 serum PSA 55 MTHFD1L gene 55 glycogen metabolism 55 neurodevelopmental outcomes 55 cardio vascular disease 55 abstinent alcoholics 55 remnant lipoproteins 55 CaPre TM 55 mood disorders 55 Hb A1C 55 comorbid disorders 55 haemodynamic 55 carotid artery thickness 55 aMCI precursor 55 esophagogastric 55 orthostatic hypotension 55 DASH diet 55 gastro oesophageal reflux 55 DQB1 * 55 triiodothyronine 55 fructosamine 55 myeloperoxidase 55 VBLOC Therapy 55 hypertensives 55 fasting glucose 55 chronic pancreatitis 55 c reactive protein 55 lignan intake 55 neuropathologic 55 hepatic function 55 biphasic insulin aspart 55 attention-deficit/hyperactivity disorder ADHD 55 waist circumference 55 atherosclerotic cardiovascular 55 alanine aminotransferase 55 causal pathways 55 Heritability 55 prediabetes 55 biochemical abnormalities 55 gestational diabetes mellitus 55 serum biomarkers 55 genetic determinants 55 total cholesterol triglycerides 55 coronary calcification 55 eNO 55 ACCOMPLISH 55 androgen deficiency 55 pharmacologic treatments 55 reducing sodium intake 55 silent myocardial ischemia 55 BPS IC 55 Adequate vitamin D 55 fatty acid oxidation 55 Adiposity 55 elevated fasting glucose 55 myopathy rhabdomyolysis 55 exudative AMD 55 neurocognitive deficits 55 premorbid 55 cardioprotective effects 55 RE LY ® 55 lipid lowering therapies 55 intermittent hypoxia 55 Gastroparesis 55 ConclusionThis 55 ischemic cardiovascular 55 LHRH antagonists 55 GH deficiency 55 acamprosate 55 variant angina 55 elevated blood glucose 55 diastolic BP 55 glycated hemoglobin HbA1c 55 SSc 55 metabolic abnormality 55 postoperative pulmonary 55 coinfected patients 55 Sociodemographic 55 prothrombotic 55 hip circumference 55 riociguat 55 pathophysiologic 55 atheroma volume 55 calcium homeostasis 55 serum aminotransferase levels 55 chromium supplementation 55 hemorrhagic complications 55 acetabular dysplasia 55 susceptibility loci 55 KIF6 carriers 55 cardiac repolarization 55 genetic variants associated 55 venous thromboembolic disease 55 arterial elasticity 55 cancer cachexia 55 direct thrombin inhibitors 55 cognitive domains 55 affective psychoses 55 morbidities 55 normotensive 55 Proteinuria 55 PCWP 55 INTERHEART 55 postprandial blood glucose 55 nitric oxide bioavailability 55 neuropsychiatric disorders 55 CC genotype 55 A1C levels 55 prefrontal cortical 55 gastrointestinal GI bleeding 55 sleep disordered breathing 55 Sleep disturbances 55 coinfection 55 pharmacokinetic parameters 55 capillary density 55 thromboembolic 55 soluble CD# ligand 55 ovarian hormones 55 elevated creatinine 55 antithrombotic 55 pituitary hormone 55 creatine supplementation 55 covariates 55 chronic thromboembolic pulmonary 55 pressor response 55 linear pharmacokinetics 55 amylin 55 artery stenosis 55 Elevated triglycerides 55 PYY 55 virological response 55 cranial irradiation 55 unmeasured confounders 55 DNA methylation patterns 55 gene polymorphisms 55 baseline serum creatinine 54 LDL particle 54 retinal thickness 54 postprandial insulin 54 thromboembolic complications 54 AUDs 54 oncologic outcomes 54 Singh Manoux 54 symptom severity 54 myeloproliferative neoplasms 54 hypoglycemic events 54 microvascular dysfunction 54 Caloric intake 54 primary hypercholesterolemia 54 glucose metabolism 54 cardiometabolic disorders 54 prenatal exposures 54 RBP4 54 saturated monounsaturated 54 distensibility 54 Insulin sensitivity 54 gut microbiota 54 carotid artery intima media 54 HMGA1 54 Atherosclerotic 54 elevated CRP 54 cognitive affective 54 angiographically 54 mixed hyperlipidemia 54 genotype phenotype 54 CVD mortality 54 TPMT 54 pathophysiological 54 G6PD deficiency 54 thyroid dysfunction 54 oral anticoagulation 54 stone formers 54 serum calcium levels 54 sedentary behaviors 54 arterial hypertension 54 HAQ DI 54 benazepril 54 pharmacological intervention 54 LDL HDL ratio 54 CINQUIL 54 nonpharmacologic 54 Logistic regression analysis 54 clinicopathologic 54 carotid stenosis 54 insulin sensitizing 54 baroreceptor reflex 54 nocturnal hypoglycaemia 54 Lipoprotein 54 thromboembolism 54 hepatic enzymes 54 serum urate 54 VLDL cholesterol 54 fatty acid composition 54 pathophysiological mechanisms 54 MUFAs 54 serum potassium 54 act synergistically 54 cerebral infarction 54 hematological parameters 54 Complications Trial 54 psychiatric comorbidity 54 LV dysfunction 54 systemic inflammation 54 SE alleles 54 adiponectin 54 rheumatic diseases 54 thrombotic events 54 endometrial hyperplasia 54 Prehypertension 54 obstructive CAD 54 developmental trajectories 54 tic disorders 54 Genetic variants 54 amyloid plaque formation 54 improves insulin sensitivity 54 HDL C 54 CETP gene 54 cerebral perfusion 54 Kidney Disease Outcomes 54 APOE e4 54 biopsychosocial 54 histologic subtypes 54 Cardiovascular Risk 54 cerebral oxygenation 54 Primary IGFD 54 apnea hypopnea index 54 glycogen synthesis 54 coronary artery atherosclerosis 54 scintigraphic 54 plasma leptin 54 arterial thickening 54 cardiac conduction 54 diastolic function 54 PLMs 54 FGFs 54 nondiabetic 54 ApoA1 54 contrast echocardiography 54 secondary efficacy endpoints 54 urinary calcium 54 myocardial ischemia 54 acarbose 54 affective psychosis 54 calcium supplementation 54 bosentan 54 BENICAR HCT 54 testosterone supplementation 54 sonographic diagnosis 54 variceal bleeding 54 nephrolithiasis 54 hypovitaminosis D 54 OSAHS 54 metformin sulphonylurea 54 prognostic variables 54 postprandial hyperglycemia 54 antitumor efficacy 54 urate levels 54 lowering LDL cholesterol 54 oxidized LDL 54 neurohormones 54 folate supplementation 54 tic severity 54 plasma creatinine 54 obese adolescents 54 SGPT 54 antioxidant intake 54 leukocyte counts 54 depressive symptoms 54 HER2 expression 54 #.#mmHg 54 nonvertebral fracture 54 anovulatory infertility 54 choline intake 54 amnestic mild cognitive impairment 54 blood lipid profiles 54 Dysregulation 54 cardiolipin 54 myocardial fibrosis 54 pulmonary capillary wedge 54 Thyroid hormone 54 aldosterone hormone 54 neuromotor 54 depressive symptom 54 antiplatelet medications 54 multivariate Cox 54 QoL 54 hemodynamics 54 insulin analogs 54 ADHD symptoms 54 pharmacologic approaches 54 exhaled nitric oxide 54 histological subtype 54 plasma fibrinogen 54 anorexia nervosa bulimia nervosa 54 peripheral insulin sensitivity 54 myocardial uptake 54 esophageal squamous cell carcinoma 54 comorbid psychiatric 54 lipid elevations 54 PROactive study 54 reflux symptoms 54 HeFH 54 extrapyramidal symptoms EPS 54 ghrelin concentrations 54 serum ferritin 54 diastolic blood pressures 54 serum bicarbonate 54 inflammatory rheumatic 54 prospectively defined 54 Hematologic 54 acute coronary syndromes 54 Syncria R 54 CYT# potent vascular disrupting 54 circadian genes 54 allostatic load 54 nonfatal myocardial infarction MI 54 glycemic 54 LDL cholesterol levels 54 CYP#D# genotype 54 primidone 54 sociodemographic 54 esophageal reflux 54 PTHrP 54 Insulin resistance 54 arterial calcification 54 parietal cortices 54 CYP#C# [001] 54 primary aldosteronism 54 dyslipidemic 54 macronutrient 54 biochemical markers 54 hyperphosphatemia 54 statistically nonsignificant 54 Endothelial dysfunction 54 lowers blood glucose 54 Hyperlipidemia 54 glitazones 54 hypervolemic hyponatremia 54 candesartan cilexetil 54 airway responsiveness 54 definite stent thrombosis 54 metabolic 54 HPA axis 54 protein excretion 54 pleiotropic effects 54 breast endometrial 54 cystatin C 54 CagA 54 Avandia Actos 54 amyloid deposition 54 dopaminergic therapy 54 peak VO2 54 SGRQ 54 genetic locus 54 Physical inactivity 54 bivariate analysis 54 predisposing factor 54 pericardial effusion 54 diabetes mellitus T2DM 54 CPAP adherence 54 QT intervals 54 lactate dehydrogenase LDH 54 anorexia nervosa bulimia 54 DASH eating 54 serum cotinine levels 54 pathogenetic 54 physiologic mechanisms 54 univariate analyzes 54 Calcium intake 54 systolic blood pressure 54 hypoglycemic episodes 54 LV ejection fraction 54 chromium picolinate supplementation 54 C Reactive Protein 54 atherosclerotic lesions 54 folic acid intake 54 sociodemographic variables 54 euthymic 54 myocardial ischaemia 54 hormone adiponectin 54 hereditary predisposition 54 plasma lipoprotein 54 INCB# [003] 54 PPAR agonist 54 clinically meaningful improvement 54 vegetable intake 54 serotonin synthesis 54 A1 allele 54 neurosensory 54 estrogen metabolism 54 physiologic parameters 54 prognostic significance 53 ADHF 53 CVD cardiovascular disease 53 LUTS 53 somatoform disorders 53 NNRTI resistance 53 bivariate analyzes 53 RBP4 levels 53 antiplatelet drugs 53 nonadherence 53 fragility fractures 53 thickness IMT 53 metaanalysis 53 HDL LDL ratio 53 baroreflex sensitivity 53 insulin resistance precursor 53 triglycerides 53 DHA supplementation 53 somatostatin analogs 53 pioglitazone HCl 53 concomitant medications 53 poststroke 53 #q# deletion 53 incretin hormones 53 apolipoprotein A1 53 Hypoglycaemia 53 systolic BP 53 skin sterol 53 Morbid obesity 53 #.#/#.# mmHg [001] 53 dopamine D2 53 hemodialysis patients 53 platelet inhibition 53 aspartate aminotransferase AST 53 ACTOS ® 53 hyperbilirubinemia 53 airway hydration 53 cardiovascular disease osteoporosis 53 pyridostigmine 53 MDRD equation 53 Djousse 53 nongenetic 53 chromosomal regions 53 methodologic 53 pulmonary toxicity 53 modifiable cardiovascular 53 AT1R 53 regulates blood glucose 53 Vitamin D insufficiency 53 metformin monotherapy 53 wholegrain foods 53 HDL Cholesterol 53 angiotensin converting enzyme 53 renal fibrosis 53 vascular reactivity 53 patients undergoing CABG 53 achieved statistical significance 53 hypercoagulable 53 triglycerides TG 53 Exacerbations 53 vascular endothelial 53 Drospirenone 53 coronary artery disease 53 paraneoplastic 53 UGT#A# * 53 abnormal lipid levels 53 carbohydrate diets 53 metabolic acidosis 53 corticosteroid dose 53 Suicidal ideation 53 dietary calcium intake 53 antigen PSA levels 53 obese postmenopausal 53 1 diabetes T1D 53 hyperactivity impulsivity 53 NATRECOR ® 53 Fasting plasma glucose 53 renal impairment 53 leiomyomas 53 cholinergic tone 53 adipokines 53 N telopeptide 53 heparin induced thrombocytopenia 53 central corneal thickness 53 polycystic ovary syndrome PCOS 53 oral antidiabetic drugs 53 vitamin D inadequacy 53 postoperative delirium 53 plasma glucose 53 prospective multicentre 53 coagulation abnormalities 53 neurocognitive impairment 53 VADT 53 tumor histology 53 dietary supplementation 53 circulating estrogens 53 PSN# [002] 53 RYGB 53 endothelin antagonists 53 airway reactivity 53 lipid lowering therapy 53 patient subpopulations 53 pharmacological treatments 53 LAGB 53 folate vitamin B# 53 leptin deficient mice 53 hormonal abnormalities 53 proteinuria 53 gastric cardia